Literature DB >> 15340732

Fibrinogen and fibrin clot structure in diabetes.

Emma J Dunn1, Robert A S Ariëns.   

Abstract

Diabetes is associated with an increased risk of developing cardiovascular disease, which is not fully accounted for by the accumulation of classic cardiovascular risk factors in patients. Recent evidence has demonstrated fibrinogen to be a powerful independent risk marker for cardiovascular disease in the general population, and it is also likely to contribute toward the increased atherosclerotic risk in diabetes. The etiology of hyperfibrinogenemia in diabetes is likely to be multifactorial, and at present the mechanisms involved have not been clarified. However, insulin, insulin resistance and inflammation are likely to be involved, especially in type 2 diabetes. The influence of diabetes in determining an individual's atherothrombotic risk is likely to extend beyond that of elevated fibrinogen levels, and may also act via changes in the structure and function of the fibrin clot that forms. Further research is needed to determine the mechanisms underlying these changes, which may lead to development of future interventions to reduce the excessive vascular risk associated with this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340732     DOI: 10.1007/s00059-004-2607-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  12 in total

1.  Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial.

Authors:  Chit Moy Ley; Qing Ni; Xing Liao; Huai-Lin Gao; Nicola Robinson
Journal:  Chin J Integr Med       Date:  2016-07-13       Impact factor: 1.978

Review 2.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

3.  Experimental and imaging techniques for examining fibrin clot structures in normal and diseased states.

Authors:  Natalie K Fan; Philip M Keegan; Manu O Platt; Rodney D Averett
Journal:  J Vis Exp       Date:  2015-04-01       Impact factor: 1.355

Review 4.  Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

Authors:  R J King; P J Grant
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

5.  Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model.

Authors:  Marlien Pieters; Namukolo Covic; Francois H van der Westhuizen; Chandrasekaran Nagaswami; Yelena Baras; Du Toit Loots; Johann C Jerling; Dale Elgar; Kathryn S Edmondson; Danie G van Zyl; Paul Rheeder; John W Weisel
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

6.  Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice.

Authors:  Heather A Cole; Tetsuro Ohba; Jeffry S Nyman; Haro Hirotaka; Justin M M Cates; Matthew J Flick; Jay L Degen; Jonathan G Schoenecker
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

7.  Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes.

Authors:  Seong-Joon Lee; Ji Man Hong; Sung Eun Lee; Dae Ryong Kang; Bruce Ovbiagele; Andrew M Demchuk; Jin Soo Lee
Journal:  BMC Neurol       Date:  2017-05-19       Impact factor: 2.474

8.  Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.

Authors:  Etheresia Pretorius; Martin J Page; Sthembile Mbotwe; Douglas B Kell
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

9.  Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Douglas B Kell
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

10.  Fibrinogen Glycation and Presence of Glucose Impair Fibrin Polymerization-An In Vitro Study of Isolated Fibrinogen and Plasma from Patients with Diabetes Mellitus.

Authors:  Boguslawa Luzak; Magdalena Boncler; Marcin Kosmalski; Ewelina Mnich; Lidia Stanczyk; Tomasz Przygodzki; Cezary Watala
Journal:  Biomolecules       Date:  2020-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.